Institut Paoli-Calmettes
Institut Paoli-Calmettes
Marseille, France35 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Feasibility Study of a Sports-Inspired Onco-Coaching Progranm for Young Adults i Cancer Remission | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Not stated | 2026-10-06 | NCT07861971 | |
| A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT06888921 | |
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-01 | NCT07701941 | |
| A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT04658862 | |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-22 | NCT06712316 | |
| Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Not stated | 2026-09-18 | NCT07827911 | |
| Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-09-18 | NCT06191263 | |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, carcinoma of esophagus, colon adenocarcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, cutaneous melanoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, esophageal disorder, fallopian tube carcinoma, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric adenocarcinoma, gonadal disorder, head and neck squamous cell carcinoma, intestinal disorder, invasive breast carcinoma, kidney cancer, kidney disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreatic adenocarcinoma, primitive neuroectodermal tumor, rectal disorder, rectal neoplasm, rectum adenocarcinoma, renal cell carcinoma, renal pelvis carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, squamous cell carcinoma, ureter cancer, ureter carcinoma, ureteral disorder, urinary bladder carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder | Recruiting | Not stated | 2026-09-14 | NCT05059444 | |
| Early Corticosteroids in Severe Influenza Pneumonia | Disease Attributes, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, Respiration Disorders, adult acute respiratory distress syndrome, infectious disease, influenza, lung disorder, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease | Not yet recruiting | Phase 3 | 2026-08-28 | NCT07786662 | |
| A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | Neoplasms by Site, brain disorder, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-21 | NCT05593094 | |
| Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-07-28 | NCT06506955 | |
| Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-07-24 | NCT06078384 | |
| Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Not applicable | 2026-07-23 | NCT06225505 | |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Adnexal Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast cancer, breast disorder, breast neoplasm, carcinoma, central nervous system malformation, cervix disorder, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, head and neck squamous cell carcinoma, hereditary disease, hereditary sensory and autonomic neuropathy, inherited neurodegenerative disorder, malignant endocrine neoplasm, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, ovarian cancer, ovarian disorder, peripheral nervous system disorder, polyneuropathy, skin disorder, squamous cell carcinoma, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-07-07 | NCT05768139 | |
| Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma Metastatic | Recruiting | Not stated | 2026-06-24 | NCT07664891 | |
| A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | HER2-Positive Primary Breast Cancer; Residual Invasive Breast Cancer | Active, not recruiting | Phase 3 | 2026-05-15 | NCT04622319 | |
| Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal cancer, rectal disorder, rectal neoplasm | Recruiting | Phase 3 | 2026-05-12 | NCT06123156 | |
| Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment | Solid Tumor | Not yet recruiting | Not stated | 2026-04-22 | NCT07545486 | |
| Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-04-22 | NCT04595565 | |
| ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast carcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-04-17 | NCT06195709 | |
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Prostatic Neoplasms, Castration-Resistant, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 / Phase 2 | 2026-04-13 | NCT06190899 | |
| Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer | Fibrosis, Head and Neck Neoplasms, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, head and neck cancer, neoplasm, skin disorder | Recruiting | Not applicable | 2026-04-13 | NCT05874492 | |
| Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-02-23 | NCT07193394 | |
| Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelioid hemangioendothelioma, hemangioendothelioma, hemangioma, low grade fibromyxoid sarcoma, myomatous neoplasm, neoplasm, neoplasm with perivascular epithelioid cell differentiation, sarcoma, vascular cancer | Recruiting | Not applicable | 2026-02-10 | NCT03967834 | |
| Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2025-11-17 | NCT05973864 |